However, the majority was grade 1 to 2, and only 19.7% of participants experienced grade 3 diarrhea.
There was no grade 4 diarrhea.Neutropenia occurred in 97.7% of participants; however, the majority was grade 1 to 2, and only 26.9% of participants experienced grade 3 to 4 neutropenia.
The objective response rate was 19.7% at 12 months (95% CI, 13.3%–27.5%).
The clinical benefit rate was 42.4%.
Median PFS was 6.0 months (95% CI, 4.2–7.5).
The most common adverse event was diarrhea, which occurred in 90.2% of the participants.
However, the majority was grade 1 to 2, and only 19.7% of participants experienced grade 3 diarrhea.